Schrödinger, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ramy Farid
- Full Time Employees
- 850
- Sector
- Technology
- Industry
- Software - Application
- Address
- 1540 Broadway New York NY United States of America 10036
- IPO Date
- Feb 5, 2020
- CIK
- 0001490978
- Website
- schrodinger.com
- Similar Companies
- Business
- Schrödinger, Inc. (SDGR) develops physics-based computational platforms that accelerate the discovery of novel molecules for drug development and materials applications. The company offers a comprehensive suite of software products and services, including its flagship Schrödinger Platform comprising physics-based simulation software such as LiveDesign for collaborative design, Desmond and FEP+ for molecular dynamics and free energy perturbation calculations; Maestro for molecular visualization and modeling; and the Materials Science Suite for property prediction and optimization; alongside cloud-based services like Schrödinger Cloud for scalable computations, consulting services for custom model development, and enterprise solutions integrating AI-driven predictions with proprietary datasets. Founded in 1990 and headquartered in New York, the company primarily serves the biopharmaceutical, biotechnology, and chemical industries, with customers spanning North America, Europe, and Asia-Pacific regions, including major players like Pfizer, Takeda, and Novartis. In recent developments within the last two years, Schrödinger expanded its offerings through strategic collaborations, such as enhanced partnerships with biotech firms for AI-hybrid drug discovery pipelines, and continued investment in machine learning integrations to its platform amid growing demand for computational efficiency in R&D.
Company News
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
BlackRock Inc. Buys New Shares in Schrodinger, Inc. $SDGR
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
Schrodinger Inc (SDGR) Stock Down 4.8% -- Now Undervalued? GF Score: 73/100
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Critical Review: Schrodinger (NASDAQ:SDGR) versus Weave Communications (NYSE:WEAV)
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript
Schrodinger Q2 Earnings Call Highlights
Schrodinger Q2 Earnings Call Highlights
Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates
Schrödinger Reports Second Quarter 2026 Financial Results
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
Schrodinger, Inc. $SDGR Shares Purchased by Amova Asset Management Americas Inc.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)